Company Snapshot

Investment Thesis

Incyte develops small molecules and biologics focused on oncology and inflammation. Jakafi cash flows fund a pipeline including Opzelura, ruxolitinib life-cycle management, and partnered immunotherapies.

  • Myelofibrosis Leadership: Jakafi remains standard of care with expansion into GVHD.
  • Dermatology Upside: Opzelura topical JAK opens large vitiligo/atopic dermatitis markets.
  • Pipeline Breadth: LIMBER combos, FGFR, and PD-1 (Zynyz) provide multiple shots on goal.

Strategic Mix

Hematology/Oncology Jakafi, Monjuvi royalties
Inflammation & Autoimmunity Opzelura, ruxolitinib cream
Partnered Revenue Eli Lilly baricitinib, Novartis capmatinib
Pipeline R&D LIMBER, oral PD-L1, bispecifics

Mix aligns with Incyte's therapeutic area disclosures.

Recent Performance

MTD TBD
QTD TBD
YTD TBD
5Y TBD

Maxim is cueing up returns data for this security. Once the nightly supported.csv job runs, these metrics will auto-populate.

Strategic Insights

Label Expansions

Pediatric vitiligo and combo therapies add Opzelura runway.

Combination Strategy

LIMBER program aims to extend Jakafi duration via combos.

Commercial Build

Derm salesforce and DTC investments accelerate awareness.

Latest Coverage

Curated headlines sourced from Maxim’s AI newsroom.

Loading latest coverage...